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Abstract: Transfusional hemosiderosis is a frequent complication in patients with transfusion 
dependent chronic diseases such as  thalassemias and severe type of sickle cell diseases. As 
there are no physiological mechanisms to excrete the iron contained in transfused red cells (1 
unit of blood contains approximately 200 mg of iron) the excess of iron is stored in various 
organs.  Cardiomyopathy  is  the  most severe  complication  covering  more than  70%  of  the 
causes of death of thalassemic patients. Although the current reference standar
deferoxamine (DFO) has been used clinically for over four decades, its effectiveness is limited 
by a demanding therapeutic regimen that leads to poor compliance. Despite poor compliance, 
because  of  the  inconvenience  of  subcutaneous  infusion
survival  and  quality  of  life  of  patients  with  thalassemia.  Deferiprone  since  1998  and 
Deferasirox  since  2005  were  licensed  for  clinical  use.  The  oral  chelators  have  a  better 
compliance because of oral use, a comparable effic
a  better  penetration  to  myocardial  cells.  Considerable  increase  in  iron  excretion  was 
documented with combination therapy of DFO and Deferiprone. The proper use of the three 
chelators  will  improve  the  prevention  an
complications, and improve survival and quality of life of transfused patients.
Introduction: Iron overload occurs when the intake 
of iron is increased over a prolonged period of time 
and is commonly seen in patients with hereditary or 
refractory  anemias  (e.g.  -thalassaemia  major, 
sickle cell anemia and myelodysplastic syndromes) 
who receive frequent blood transfusions. The iron 
excess  is  initially  stored  in  the  reticuloendotelial 
system, which has a capacity of about 10
then in all parechymas,
1 resulting in life
complications,  namely  cardiopathy,  liver  and 
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osiderosis is a frequent complication in patients with transfusion 
dependent chronic diseases such as  thalassemias and severe type of sickle cell diseases. As 
there are no physiological mechanisms to excrete the iron contained in transfused red cells (1 
nit of blood contains approximately 200 mg of iron) the excess of iron is stored in various 
organs.  Cardiomyopathy  is  the  most severe  complication  covering  more than  70%  of  the 
causes of death of thalassemic patients. Although the current reference standar
deferoxamine (DFO) has been used clinically for over four decades, its effectiveness is limited 
by a demanding therapeutic regimen that leads to poor compliance. Despite poor compliance, 
because  of  the  inconvenience  of  subcutaneous  infusion,  DFO  improved  considerably  the 
survival  and  quality  of  life  of  patients  with  thalassemia.  Deferiprone  since  1998  and 
Deferasirox  since  2005  were  licensed  for  clinical  use.  The  oral  chelators  have  a  better 
compliance because of oral use, a comparable efficacy to DFO in iron excretion and probably 
a  better  penetration  to  myocardial  cells.  Considerable  increase  in  iron  excretion  was 
documented with combination therapy of DFO and Deferiprone. The proper use of the three 
chelators  will  improve  the  prevention  and  treatment  of  iron  overload,  it  will  reduce  
complications, and improve survival and quality of life of transfused patients.
Iron overload occurs when the intake 
of iron is increased over a prolonged period of time 
and is commonly seen in patients with hereditary or 
thalassaemia  major, 
sickle cell anemia and myelodysplastic syndromes) 
ent blood transfusions. The iron 
excess  is  initially  stored  in  the  reticuloendotelial 
system, which has a capacity of about 10-15 g, and 
resulting in life-threatening 
complications,  namely  cardiopathy,  liver  and 
endocrine  dysfunction  and  reduced  patient’s 
survival.
2,3,4 Iron  excess  also  increases  cell 
concentration  of  iron-binding  proteins  such  as 
ferritin  and    haemosiderin  complexes    in 
lysosomes
5.  Non-transferrin
iron  in  low  molecular  weight  forms,  may  initiate 
free  radicals  reactions.
6
thalassaemia require  regular  blood  transfusion in 
order  to  have a  normal  life.  Correct management 
inhibits bone marrow hyperactivity and delays the 
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osiderosis is a frequent complication in patients with transfusion 
dependent chronic diseases such as  thalassemias and severe type of sickle cell diseases. As 
there are no physiological mechanisms to excrete the iron contained in transfused red cells (1 
nit of blood contains approximately 200 mg of iron) the excess of iron is stored in various 
organs.  Cardiomyopathy  is  the  most severe  complication  covering  more than  70%  of  the 
causes of death of thalassemic patients. Although the current reference standard iron chelator 
deferoxamine (DFO) has been used clinically for over four decades, its effectiveness is limited 
by a demanding therapeutic regimen that leads to poor compliance. Despite poor compliance, 
,  DFO  improved  considerably  the 
survival  and  quality  of  life  of  patients  with  thalassemia.  Deferiprone  since  1998  and 
Deferasirox  since  2005  were  licensed  for  clinical  use.  The  oral  chelators  have  a  better 
acy to DFO in iron excretion and probably 
a  better  penetration  to  myocardial  cells.  Considerable  increase  in  iron  excretion  was 
documented with combination therapy of DFO and Deferiprone. The proper use of the three 
d  treatment  of  iron  overload,  it  will  reduce  
complications, and improve survival and quality of life of transfused patients.
on  and  reduced  patient’s 
Iron  excess  also  increases  cell 
binding  proteins  such  as 
ferritin  and    haemosiderin  complexes    in 
transferrin-bound-iron  (NTBI), 
iron  in  low  molecular  weight  forms,  may  initiate 
6 Patients  with  -
thalassaemia require  regular  blood  transfusion in 
order  to  have a  normal  life.  Correct management 
inhibits bone marrow hyperactivity and delays the Medit J Hemat Infect Dis 2009; 1 (1 ); Open Journal System 
appearance  of  hypersplenism.  Their  mean  annual 
intake is 165 or 140 mg of pure red cells/Kg (for 
non  splenectomized  and  splenectomized  patients, 
respectively),  which  corresponds  to  0,49-0,44 
mg/Kg/day.
7 Prior to the introduction of chelating 
therapy,  most  patients  did  not  reach  the  second 
decade of life, mainly owing to heart disease.
8  
Desferrioxamine:  The  hexadentate  chelator 
desferrioxamine B (DFO) was identified as the first 
effective biologically active Fe chelator. Released 
in the 1960s  as the first clinically approved chelator 
for  the  treatment  of  iron  overload,  DFO  has 
significantly improved the life expectancy and the 
quality of life of patients with iron overload
9 who 
previously would not have survived after their teen 
years. Moreover, it had been the gold standard in 
iron  chelation  therapy.  The  ability  of  a  chelating 
agent  to  penetrate  cells  depends  on  its  molecular 
size and affinity for lipids. For its large molecular 
size  (molecular  weight  656  Daltons)  and  low 
affinity for lipid, DFO is poorly absorbed from the 
gastrointestinal  tract.
10 It  is  not  orally  active, 
undergoes rapid renal elimination. Thus, it must be 
administrated only  parenterally. Its plasma half-life 
is short ( ~20 minutes). It binds iron very strongly 
with a ratio of 1:1. The usual dose of DFO is 20 to 
60 mg/Kg/die. It is subcutaneously administered via 
a battery-operated  portable pump over a period of 
8-12 hours overnight, for 5 to 7 nights per week.  
This has resulted in a large proportion of patients (~ 
33%) failing to comply with this regimen.
11
Deferiprone: Deferiprone is a synthetic, bidentate 
iron  chelator.  Three  molecules  of  deferiprone  are 
required to bind one atom  of iron. Deferiprone also 
binds other metals including zinc; zinc deficiency 
has been reported in a small number of patients with 
iron overload receiving long-term deferiprone.
12 It 
is  orally  administered  at  75  mg/Kg/day  in  three 
divided  doses.  Compliance  rates  with  deferiprone 
are  generally  higher  than  those  associated  with 
subcutaneous  infusions  of  desferrioxamine.
13 The 
molecule undergoes extensive liver metabolism and 
> 85% of the administered dose is recovered in the 
urine as a non-chelating O-glicuronide conjugate. It 
is excreted predominantly via the renal system  as 
the parent compound, its conjugate and as an iron-
bound complex. The urinary iron excretion obtained 
with a dose of 75 mg/Kg is comparable with that 
obtained  with  40-50  mg/Kg  DFO  infusion,  while 
iron  excretion  in  the  stool  is  negligible.  
Deferiprone was introduced in Europe in 2000 as 
second-line therapy for -thalassemia patients with  
DFO–related adverse events or contraindications to 
DFO. In general, the above indicated oral daily dose 
is  required  for  the  treatment  of  iron  overload 
condition, although some investigators have used up 
to 100 mg/Kg/day. The most frequent deferiprone-
related  adverse  reactions  are  gastrointestinal 
adverse  reactions  (nausea,  abdominal  pain, 
vomiting)    and  arthralgia,  while  the  most  serious  
adverse event is  agranulocytosis.
12 In a multi-centre 
study    designed    to  evaluate  the  incidence  of 
agranulocytosis   (neutrophil count of < 0.5 x 10
9/L) 
in patients treated with deferiprone, 1 patient out of 
187  (0,5%)  was  affected  by  this  condition  and  9 
patients  (4,5%)  had  moderate  neutropenia  (two 
consecutive  neutrophil  counts  of    1.5  x  10 
9  /L) 
within  the  first    year  of  treatment.
14 Over  the 
following  three  years,  there  were  no  cases  of 
agranulocytosis observed and  seven  new  cases  of 
moderate neutropenia were reported.
15 In an Italian 
study conducted in 532 patients with -thalassemia 
treated for a total of 1154 patients-years, the rates  
of agranulocytosis and neutropenia were 0.43 and 
2.08  respectively,  per  100  patients-years.
16 An 
idiosyncrasic  pathogenesis can be hypothesized.
17
Generally it is more frequent during the first year of 
deferiprone  treatment.  Agranulocitosys  is 
sometimes reversible when the drug is stopped but 
sometimes  can  be  necessary  to  quickly  begin 
therapy  with  GCS-F.  For  elevated  incidence  of 
relapse, it is not suitable to submit the patient to the 
same  therapy.  An  interesting  advantage  of 
deferiprone  over  DFO  seem  to  be    its  ability  to 
reduce  cardiac  iron  levels  in  patients  with  -
thalassemia, wich is probably due to the small size 
of the molecule (molecular weight 139 versus 656 
Dalton  for  DFO)  and  to  its  lipophilic  properties.
Anderson  et  al.
14,15,18 demonstrated  that  patients 
with -thalassemia treated with deferiprone (n=15) 
presented  a  significantly  (p=0.02)  elevated 
myocardial  T2*  value,  an  RMI  variable  with 
inverse correlation to tissue iron levels, compared 
with that of mached control patients ( n=30) treated 
with  DFO, and that  more than  half (67%)  of the 
patients  treated  with  DFO  were  not  protected 
against cardiac siderosis. In contrast, almost three 
quartes  (73%)  of  deferiprone  recipients  were 
protected against cardiac siderosis.
19 Furthermore in 
such patients who were randomized to  open-label 
deferiprone at mean dose of 92 mg/Kg (n=29) or 
who  continued  to  receive  subcutaneous  DFO  at 
standard dose (n=32) , improvements from baseline 
in  myocardial  T2*  values  at  12  months  (primary 
endpoint)  were  significant  for  both  groups  (p< 
0.001  for both  groups),  but  the  between-group Medit J Hemat Infect Dis 2009; 1 (1 ); Open Journal System 
difference was significantly in favor to deferiprone 
(27% versus 13% improvement; p< 0.0023). In the 
same study, in patients treated with deferiprone, left 
ventricular  ejection  fraction  improved  by  3.1%  ( 
absolute units), compared with 0.32% improvement 
in  DFO-treated  patients  (p=0.003  versus  DFO).
20
Recently,  some  authors  in  a  multicenter, 
prospective,  long-term  (7  years  and  4  months) 
randomized  trial  on  265  enrolled  thalassemic 
patients,  have shown an  improving of  survival  in 
patients    with  deferiprone  treatment  (alone  or  in 
sequential  or  in  association  with  DFO)  versus 
DFO.
21    Recently  El-Beshlawy  et  al.  in  a  multi-
centre  24  week  study  period  on  100  young 
thalassemic patients  10 years old showed that the 
a new liquid formulation had a lower incidence of 
gastrointestinal  adverse  reactions  that  previously 
reported with the tablet formulation (13% vs 42%), 
no  important  changes  about  neutropenia  or 
agranulocytosis  were  observed.
22 Hoffbrand’s  
metanalysis
18 demonstrated  that  treatment  with 
deferiprone leads to a negative iron balance in some 
but not in all patients. Factors that may contribute to 
inter-individual response variation are the degree of 
iron  overload,  therapy  duration,  dosage,  and 
compliance. One  explanation  for  individual 
variation in response to the drug is that deferiprone 
is  inactivated  by  glucuronidation,  which  may  be
very rapid in some individual.
12
Combined therapy: Deferiprone can be associated 
to  DFO    when  the  chelation  response  is 
unsatisfactory or under conditions of serious cardiac 
siderosis with or without heart failure, in conditions  
with  high  risk  of  morbility  or  mortality.  The 
efficacy  of  the  combination  of  a  low  molecular 
weight chelating agent that is able to penetrate cells 
efficiently, with a high molecular weight chelating 
agent that is able to form a stable association with 
iron  and  thus  achieve  a  satisfactory  urinary  iron 
excretion,  has  been  shown  in  several  clinical 
studies.
23-25 Combination therapy leads a reduction 
of  plasma  ferritin  levels  in  patients  in  which 
monotherapy with deferiprone failed to produce a 
satisfactory outcome
26 and shows  an additive effect 
on  the  urinary  excretion  of  iron.
27 Tanner  et  al 
demonstrated  that,  compared  with  DFO 
monotherapy,  combination  therapy  significantly 
improved  myocardial  T2*  values  (primary 
endpoint), plasma ferritin levels, LVEF, endothelial 
function.
23 This approach has also proven effective 
in the acute phase treatment of heart failure caused 
by iron overload.
29,30 Recently, the beneficial effect 
of combination therapy on the pancreatic endocrine 
damage  secondary  to  hemosiderosis  has  been 
described.
30 The mortality due to cardiac damage is 
strongly reduced  by means  of T2*  cardiovascular 
magnetic  resonance  and  combined  therapy  with 
deferiprone and desferrioxamine.
31
Deferasirox: Deferasirox (ICL670) is  a  new  iron 
chelator  orally  bioavailable.  Well  as  Thalassemia 
Major and Intermedia,  it has been used in many 
others chronic anemias transfusions dependent such 
as Sickle Cell Disease (SCD), Diamond Blackfan 
anemia,  Myelodysplastic  Syndromes  (MDS)    and 
other  rare  anemias.  In  2005,  Food  and  Drug 
Administation (FDA),
32 and afterward the European 
Medicine  Agency  (EMEA)
33 approved  its  use  in 
Thalassemia  Major  patients  (aged  ≥  6  years),  
transfused  with  ≥  7ml/kg/month  of  packed  red 
blood cells. Deferasirox therapy is allowed also in 
the  following  groups  of  multitransfused  iron 
overloaded  patients  when  treatment  with  DFO  is 
contraindicated  or  inadeguate:  Thalassemia  Major 
patients transfused with <7ml/kg/month of packed 
red blood cells, Thalassemia Major patients aged 2-
5  years,  patients  affected  by  other  anemias. 
Actually, Deferasirox is available in 90 nations.
34
Deferasirox, a N-substituted bis-hydroxyphenyl-
triazoles  compound,  belongs  to  a  new  class  of 
tridentate  iron  chelators.  It  was  selected  among 
more  than  700  molecules  because  it  is  orally 
administrable  and  it  gave  the  best  therapeutic 
results.
34,35 Two molecules of Deferasirox are able
to generate a stable complex with one molecule of 
iron. Its half life (t1/2) is between 8 and 16 hours, 
allowing a once-daily administration. After the oral 
administration  (dissolved  in  water  or  orange  or 
apple juice)  it  is  rapidly absorbed  and its  plasma
level is in the therapeutic range for 18 to 24 hours
36. 
Thus, after a dose, the chelating effect lasts all day. 
The  lowest  plasma level of the  drug, during the 
day,  corresponds  to  25%  of  the  peak  of  drug  
plasma concentration. 
Deferasirox  protects  cells  from  the  toxicity  of 
Non Transferrin-Bound serum Iron (NTBI) and of 
Labile  Plasma  Iron  (LPI).  The  last  generates 
Reactive  Oxigen  Species  (ROS)  able  to  damage 
cells
37. High LPI values, if they frequently occur, 
can  affect  the  most important organ  function and 
the patient survival.
38 Also the other chelators (DFO  
and Deferiprone) have this protective action but, for 
their shorter half-life, this is not continuous. On the 
contrary,  Deferasirox  assures  a  more  constant 
chelation during the day.  Daar et al demonstrated  
that Deferasirox, after two hours of the oral intake 
in  the  morning,  reduces  LPI  levels.  During  theMedit J Hemat Infect Dis 2009; 1 (1 ); Open Journal System 
Table 1. Side effect overview. 
Side effects Frequence
( Patient %) Notes
Abrupt creatinine elevation  36
Mild;    generally  it  remains  within  the 
normal  range;  often  spontaneously 
regresses; the  reduction of the dose  can 
normalize creatinine level
Gastroenteric disorders 
(nausea, vomit, diarrhea, abdominal pain) 26 Dose-dependent;  mild-moderate; 
generally they regress
Rash 7 Dose-dependent;  mild-moderate; 
generally they regress
Liver enzyme elevation 2
Not dose dependent: Often liver enzymes 
were  high  before  starting  the  therapy. 
Elevation> 10 UI are not common (0.3%)
Reduction of hearing Cataract ≤1 Not common
treatment,  if  the  drug  intake  is  regular,  the  LPI, 
measured before the daily dose, tends to decrease 
and  subsequently    LPI  values  reach  the  normal
range.
30,40
If  Deferasirox  is    taken  with  food,  its 
bioavaibility  changes  overall  according  to  the  fat  
content of the meal. For this reason the drug must 
be taken at least 30 minute before eating, preferably 
at  the  same  time  every  day.
41 The  patient  age  is 
another  parameter  influencing  the  bioavailability 
which is lower for the adolescents (12-17 years old) 
and children (2-12 years old). 
Metabolism and elimination of deferasirox and 
the iron chelate (Fe-[deferasirox]2) is primarily by 
glucuronidation followed by hepatobiliary excretion 
into  the  feces  (83%). A  enterohepatic  circulation, 
after a decojugation of glucuronidated drug in small 
bowel, is supposed.
Many clinical trials, performed in patient groups 
with  transfusion-dependent  anemias,  demonstrated 
Deferasirox efficacy.
36,43,46 For this purpose serum 
ferritin  and  Liver  Iron  Concentration  (LIC)  were 
monitored.  These  study  showed  that  a  relation 
between  the  drug  dose  administered  and  the 
reduction of body iron index is present and  this is a 
function of iron intake though transfusions.
47,48 In 
fact, treating, multitransfused β-thalassemia patients 
with  20  and  30mg/kg/die,  a  mean  LIC  reduction 
ranging from -0.4 and -8.9 mg Fe/g of dry weight 
and a mean ferritin reduction ranging from  -36 and 
-926 μg/l were observed. These result obtained after 
an year were confirmed after a follow-up of 5 years-
Moreover, during this time, the number of patients 
who  reached  a  LIC<7  mg  Fe/g  dw    and  serum 
ferritin  <  1000  g/l  progressively  raised  (35% 
versus  45%  for  LIC  and  12%  versus  33%  for 
ferritin).
49
Analysis of registration study results, indicated 
that the Deferasirox dose must be set in function of 
transfusion  regimen  and  in  function  of  the 
therapeutic  target:  reduction  of  iron  overload  or 
maintenance of iron balance. The daily dose of 20 
mg /kg/ was able to obtain a neutre/negative iron 
balance in 47% of patients with high blood supply, 
in 55% of patients with intermediate blood supply 
and in 75% of patients with low blood supply. The 
daily dose of 30 mg/kg was sufficient to reduce iron 
overload in 82% of patients with high blood supply, 
in 83% of patients with intermediate blood supply 
and  in  96%  of  patients  with  low  blood  supply. 
Thereafter  30  mg/kg/die  is  the  starting  dose  to 
reduced  iron  overload  in  regularly  highly  
multitransfused patients.
50  
Recently  EPIC  study  results  were  published.
51
This  study  was  performed  examining  1744 
multitransfused  overloaded  patients:  1115  β
thalassemic (63.9%); 341 with MDS (19.6%); 116 
with Aplastic Anemia (6.7%); 80 SCD (4.6%); 43 
with    rare  anemias  (2.5%)  and  other  anemias 
including  cancer  anemias  (2.9%).  For  a  mean 
Deferasirox  dose  of  22,2  mg/kg/die  and  an  iron 
intake of 0.41 mg Fe/kg/die, the mean serum ferritin 
reduction  was  264  ng/ml.  In  a  cohort  of  patients 
treated  with  30  mg/kg/die  or  more  the  highest
reduction of ferritin was registered (-882 ng/ml with 
an iron intake of 0.37 mg Fe/kg/die).
The ESCALATOR study
52 included 237 patients 
with    high  overload  and  not  responders  to  other 
chelators. They were treated with Deferasirox dose 
> 30mg/kg/die. The mean basal LIC was 20.1 mg 
Fe/g dw; at the end of the study ( after 2,7 years) the Medit J Hemat Infect Dis 2009; 1 (1 ); Open Journal System 
Table  2. Characteristics of Cheletors at present available.
Charatteristics Deferoxamine Deferiprone Deferasirox
Dose ( mg/Kg/day) 25-60 75 20-30
Route of administration sc,ev  (  8-12  hours,  5days 
/week) Orally, three times/day Orally, once a day
Half life 20-30 min 3-4 hours 8-18 hours
Excretion Urine, stools Urine Stools
Most important side effects
Local  skin  reactions, 
allergies,  neuro-sensorial 
damage, growth retardation
Gastroenteric  disorders, 
agranulocytosis / neutropenia 
arthralgias,  liver  enzyme 
elevation
Gastroenteric disorders, rush, 
mild  not  progressive 
creatinine  elevation,  liver 
enzyme elevation
Status Approved Approved except in USA/Canada Approved
mean LIC was significantly lower:  11.8 mg Fe/g 
dw (P<0.0001).
53 The cardiac T2* was evaluated in 
19  patients  of  the  ESCALATOR  study:  this 
parameter  showed  a  significant  improvement, 
independently to the mean basal values.
54
Moreover,  in  multitransfused  patients 
Deferasirox  is  efficacious  in  reducing  cardiac 
overload and in preventing it.
55-57 In fact, in 100 β
thalassemic, in a period of 2 years, an improvement 
of  T2*  of  40,8%  was  observed  (mean  T2*  11.2
msec  versus  12,9  msec  p<0.0001).  In  78  β
thalassemic with normal basal T2* after a year no 
change  was  observed.  Finally  in  those  patients 
showing a basal T2* ranging between 10 and  20 
msec, a mean dose of 34.5±4.8 mg/kg/die  for two 
years  normalized the  T2*:  Δ%  =  +48.1%;    basal 
T2*    14.6  msec  versus  final  T2*  20,4  msec; 
p<0.001.
Moreover  Deferasirox  is  a  safe  and  well 
tolerated drug in adults and children both in short 
and long treatment periods. In registration studies 
after 5 years, no new  side effects were reported and 
no  change  in  the  incidence  of  those  already 
reported. The frequency of the most common side 
effects has been progressively decreasing.
36, 43-46,51-57
Table  1 summarized  the  most  important 
reported side effects. At present, this drug is largely 
employed. Among the side effects not reported in 
registration  studies,  cytopenias  occurred,  although 
mainly  in  patients  with  predisposing  clinical 
conditions.  The  exact  role  of  Deferasirox  in 
inducing  cytopenias  is  not  defined.  Nevertheless, 
regular controls of complete and differential blood 
counts are recommended. Renal and liver failures 
and  bleeding  from  the  gastroenteric  tract  were 
reported.  Similarly  to  cytopenias,  in  the  clinical 
history  of  these  patients,  predisposing  conditions 
able  to  induce  these  complications  are  often 
recognizable.  Before  starting  Deferasirox  therapy, 
the  careful  patient  physical  examination,  the 
accurate  medical  history  registration  and    the 
detection of the most common laboratory tests are 
crucial for a safe use of the drug.
58      
The results of many clinical trials and studies are 
consistent  with  the  evidence  that  Deferasirox  is 
efficacious in removing and in preventing the liver 
and cardiac iron overload, in chelating free iron for 
24 hours and it is safe and well tolerated also if high 
doses (up to 40 mg/kg/die) are used.
Table 2 show the most important feature of iron 
chelators commercially available 
Conclusions:  The  recent  expansion  of 
erythrocyte  transfusional  therapy  to  pediatric 
patients with sickle cell disease and an elevated risk 
of  stroke
59 and  in  some  type  of  thalassemia 
intermedia associated with bone deformations and 
growth  defects,  has  increased  the  population  of 
pediatric patients requiring chelation  therapy. The 
knowledge of  the  properties  of  the available  iron 
chelating  agents  and  of  individual  patient 
requirements,  coupled  with  effective  methods  to 
accurately  monitor  iron  levels,  has  enabled  iron 
chelation  therapy  to  be  highly  personalized.  The 
recently available oral chelators offer a convenient 
administration regimen, overcoming the burden of a 
subcutaneous  infusions  of  DFO  and  potentially 
improving  compliance.  Treating  patients  with 
tailored  therapy  will  eventually  lead  to 
improvement in morbidity and mortality induced by 
iron toxicity.Medit J Hemat Infect Dis 2009; 1 (1 ); Open Journal System 
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